A Phase 1 Randomized Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Escalating Oral Doses of Dordaviprone and the Effects of Food on the Bioavailability of Dordaviprone in Healthy Adult Subjects
Clinical Pharmacology in Drug Development · 2025
DOI: 10.1002/cpdd.1512 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Shamia L Faison und 7 weiteren Autor:innen. Beteiligte Einrichtung: Certara Strategic Consulting, Princeton, NJ, USA. Hauptthemen laut MEDLINE: Food-Drug Interactions, Pyridones, Antineoplastic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Dordaviprone (ONC201) is a novel, small molecule imipridone with antitumor effects in glioma patients. This study evaluated the pharmacokinetics and safety of dordaviprone following single escalating doses (Part A), as a capsule content mixed with applesauce or Gatorade (sports drink) [Part B1]), and with or without food [Part B2]. The most common treatment‐emergent adverse events pooled across study parts (Parts A, B1, and B2) were headache, dizziness, and headache, respectively; all were mild. Systemic dordaviprone exposure increased dose proportionally following administration of 125‐625 mg of dordaviprone. Following dordaviprone capsule contents sprinkled on applesauce or dissolved in sports drink, the geometric mean ratios, and 90% confidence intervals (CIs) of the dordaviprone area under the concentration versus time curve (AUC) fell within the bioequivalence (BE) limits of 80.00%‐125.00%; however, for C max the 90% CI lower limit (0.70) fell below BE limits when sprinkled on applesauce. The geometric mean ratios and 90% CIs of dordaviprone administered under fed versus fasted conditions fell within BE limits of 80.00%‐125.00% for the AUC, indicating no food effect on total exposure; however, maximum concentration (C max ) (90% CI 0.55, 0.67) fell below BE limits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Certara Strategic Consulting, Princeton, NJ, USA.
- Consultant.
- Chimerix, Inc., Clinical Pharmacology and Translational Medicine, Durham, NC, USA.
Zitieren
APA
Faison, S. L., Batonga, J., Arumugham, T., Bartkus, A., Morrison, M., Mullin, M. J., Tippin, T., & Naderer, O. (2025). A Phase 1 Randomized Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Escalating Oral Doses of Dordaviprone and the Effects of Food on the Bioavailability of Dordaviprone in Healthy Adult Subjects. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1512
Vancouver
Faison SL, Batonga J, Arumugham T, Bartkus A, Morrison M, Mullin MJ, et al. A Phase 1 Randomized Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Escalating Oral Doses of Dordaviprone and the Effects of Food on the Bioavailability of Dordaviprone in Healthy Adult Subjects. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1512
BibTeX
@article{Faison2025,
author = {Faison, Shamia L and Batonga, Joelle and Arumugham, Thangam and Bartkus, Angela and Morrison, Marion and Mullin, Mark J and Tippin, Tim and Naderer, Odin},
title = {A Phase 1 Randomized Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Escalating Oral Doses of Dordaviprone and the Effects of Food on the Bioavailability of Dordaviprone in Healthy Adult Subjects},
journal = {Clinical Pharmacology in Drug Development},
year = {2025},
doi = {10.1002/cpdd.1512}
}
EUVIMED